Researchers at the University of Cambridge report that they have used artificial intelligence (AI) to develop a novel vaccine component intended to protect against a broad range of coronaviruses. According to the BBC, the team says this is the first time a vaccine’s key component was entirely designed by AI and then tested in humans.
What was designed and how it works
The researchers analysed genetic sequences from multiple coronaviruses collected by surveillance programs. An AI system processed these data and produced a so-called "superantigen": an artificially designed immunological target meant to train the immune system to recognise not just current variants but the wider coronavirus family.
First human trial: safety and immune response
In the initial human study, 39 volunteers took part; the trial primarily assessed safety. The reported immune response so far has been modest, but the research team and outside experts view the findings as encouraging given the new approach.
Why this matters
Professor Jonathan Heeney says the aim is for science to gain a lead over pathogens — to prepare for future pandemics rather than merely react to current viruses. The approach could enable faster and more broadly protective vaccine design, particularly for pathogens that mutate rapidly or jump from animals to humans.
Related efforts and expert views
Professor Saul Faust highlights that AI-guided design could be especially valuable for rapidly changing viruses by enabling more effective vaccine development. The Cambridge group is already applying similar methods to develop a universal influenza vaccine, a vaccine against H5N1 avian influenza, and protection against Ebola viruses.
Andy Pollard, head of the Oxford Vaccine Group, has said AI could become a "game-changing" technology in vaccine development because it can more quickly predict how the immune system will respond to a new vaccine.
Next steps
The current results require further enhancement and larger clinical trials to determine whether an AI-designed superantigen can provide broad and durable protection in the human population. While the work is promising, confirmation of efficacy and widespread applicability will need additional evidence.
